Melittin-incorporated nanomedicines for enhanced cancer immunotherapy
Journal of Controlled Release · 2024-11 · 375 · 285-299
DOI: 10.1016/j.jconrel.2024.08.047 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2024-11. Verfasst von Xuefeng Duan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, The Second Hospital of Jilin University, 4026 Yatai Street, Changchun 130041, PR China. Hauptthemen laut MEDLINE: Melitten, Neoplasms, Immunotherapy, Nanomedicine. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 111 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Youth Innovation Promotion Association of the Chinese Academy of Sciences, Jilin Provincial Scientific and Technological Development Program.
Abstract (Originalsprache)
Immunotherapy is a rapidly developing and effective strategy for cancer therapy. Among various immunotherapy approaches, peptides have garnered significant attention due to their potent immunomodulatory effects. In particular, melittin emerged as a promising candidate to enhance cancer immunotherapy by inducing immunogenic cell death, promoting the maturation of antigen-presenting cells, activating T cells, enhancing the infiltration and cytotoxicity of effector lymphocytes, and modulating macrophage phenotypes for relieving immunosuppression. However, the clinical application of melittin is limited by poor targeting and systemic toxicity. To overcome these challenges, melittin has been incorporated into biomaterials and related nanotechnologies, resulting in extended circulation time in vivo, improved targeting, reduced adverse effects, and enhanced anti-cancer immunological action. This review provides an in-depth analysis of the immunomodulatory effects of melittin-incorporated nanomedicines and examines their development and challenges for clinical cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology and Obstetrics, The Second Hospital of Jilin University, 4026 Yatai Street, Changchun 130041, PR China.
- Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun 130022, PR China.
- Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun 130022, PR China. Electronic address: jzyang@ciac.ac.cn.
- Department of Orthopedics, The Second Hospital of Jilin University, 4026 Yatai Street, Changchun 130041, PR China.
- Department of Gynecology and Obstetrics, The Second Hospital of Jilin University, 4026 Yatai Street, Changchun 130041, PR China. Electronic address: xutianmin@126.com.
- Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, Changchun 130022, PR China. Electronic address: jxding@ciac.ac.cn.
Förderung
- National Natural Science Foundation of China
- Youth Innovation Promotion Association of the Chinese Academy of Sciences
- Jilin Provincial Scientific and Technological Development Program
Zitieren
APA
Duan, X., Zou, H., Yang, J., Liu, S., Xu, T., & Ding, J. (2024). Melittin-incorporated nanomedicines for enhanced cancer immunotherapy. Journal of Controlled Release, 375, 285-299. https://doi.org/10.1016/j.jconrel.2024.08.047
Vancouver
Duan X, Zou H, Yang J, Liu S, Xu T, Ding J. Melittin-incorporated nanomedicines for enhanced cancer immunotherapy. Journal of Controlled Release. 2024;375:285-299. doi:10.1016/j.jconrel.2024.08.047
BibTeX
@article{Duan2024,
author = {Duan, Xuefeng and Zou, Haoyang and Yang, Jiazhen and Liu, Shixian and Xu, Tianmin and Ding, Jianxun},
title = {Melittin-incorporated nanomedicines for enhanced cancer immunotherapy},
journal = {Journal of Controlled Release},
year = {2024},
volume = {375},
pages = {285--299},
doi = {10.1016/j.jconrel.2024.08.047}
}
EUVIMED